Strategic partnerships The company has a history of collaboration with major players (Agilent in 2021, Crucial Data Solutions in 2024) indicating openness to ecosystem partnerships that could expand channel reach and co-development of assays and automation workflows.

High value offerings SISCAPA enables highly sensitive multiplexed protein quantitation across large dynamic ranges, marketed as a robust alternative to traditional immunoassays, positioning it to attract biopharma, CROs, and clinical lab partners needing precise biomarker analysis.

Automation and throughput The automated workflow designed for LC-MS/MS platforms supports high-throughput and scalable data generation, suggesting sales potential with labs pursuing rapid biomarker validation, clinical LC-MS workflows, and LDT development.

Small team, targeted expansion With a lean workforce (2-10 employees) and revenue in the 1–10M range, there is an opportunity to partner with systems integrators, contract service providers, or partner channels to accelerate market penetration and productization.

Platform and data synergy Current partnerships and a kinase of prior NCI SBIR collaboration imply potential in oncology biomarker projects; target customers include pharma/biotech R&D groups seeking validated, reusable SISCAPA reagents and assay development services.